You are here:

atomoxetine (Strattera)

Advice

following an abbreviated submission

atomoxetine oral solution (Strattera®) is accepted for restricted use within NHS Scotland.

Indication under review: treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.

SMC restriction: to use in patients who are unable to swallow capsules.

Atomoxetine oral solution demonstrated bioequivalence to atomoxetine capsules. The availability of the oral solution will provide a formulation acceptable to patients who cannot swallow capsules. Any overall budget impact is likely to be small.

Drug Details

Drug Name: atomoxetine (Strattera)
SMC Drug ID: 1107/15
Manufacturer: Eli Lilly and Company Ltd
Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.
BNF Category:
Sub Category: 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 7 December 2015

Back